Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
43
RNXT Quote, Financials, Valuation and Earnings
Last price:
$0.98
Seasonality move
:
66.77%
Day range:
$0.93 - $1.00
52-week range:
$0.70 - $1.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
33.27x
P/B ratio:
4.36x
Volume:
201.9K
Avg. volume:
333K
1-year change:
-32.87%
Market cap:
$35.2M
Revenue:
$43K
EPS (TTM):
-$0.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RNXT
RenovoRx, Inc.
|
$304K | -$0.08 | 680.23% | -33.17% | $5.56 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.96% | -57.14% | $27.25 |
|
DYAI
Dyadic International, Inc.
|
$1.1M | -- | 64.34% | -- | $7.00 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
PIII
P3 Health Partners, Inc.
|
$346.6M | -$0.09 | -3.88% | -- | $10.25 |
|
XNCR
Xencor, Inc.
|
$28.7M | -$0.70 | -43.5% | -5.69% | $28.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RNXT
RenovoRx, Inc.
|
$0.96 | $5.56 | $35.2M | -- | $0.00 | 0% | 33.27x |
|
ADMA
ADMA Biologics, Inc.
|
$19.80 | $27.25 | $4.7B | 23.25x | $0.00 | 0% | 9.97x |
|
DYAI
Dyadic International, Inc.
|
$1.00 | $7.00 | $36.2M | -- | $0.00 | 0% | 9.30x |
|
GTBP
GT Biopharma, Inc.
|
$0.64 | $8.00 | $6.8M | -- | $0.00 | 0% | 59.35x |
|
PIII
P3 Health Partners, Inc.
|
$5.05 | $10.25 | $16.5M | -- | $0.00 | 0% | 0.01x |
|
XNCR
Xencor, Inc.
|
$16.81 | $28.00 | $1.2B | -- | $0.00 | 0% | 8.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RNXT
RenovoRx, Inc.
|
2.84% | 2.836 | 0.51% | 5.42x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
DYAI
Dyadic International, Inc.
|
66.01% | 0.231 | 11.86% | 2.76x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
PIII
P3 Health Partners, Inc.
|
107.59% | -0.008 | 396.37% | 0.28x |
|
XNCR
Xencor, Inc.
|
24.45% | 1.841 | 24.19% | 5.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RNXT
RenovoRx, Inc.
|
$213K | -$3.2M | -124.83% | -127.86% | -1203.01% | -$2.3M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
DYAI
Dyadic International, Inc.
|
$140.6K | -$1.9M | -106.46% | -413.59% | -164.23% | -$1.9M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
PIII
P3 Health Partners, Inc.
|
-$45.6M | -$44.2M | -89.85% | -223.63% | -12.81% | -$15.5M |
|
XNCR
Xencor, Inc.
|
$18.4M | -$47.5M | -15.54% | -20.07% | -226.29% | -$31M |
RenovoRx, Inc. vs. Competitors
-
Which has Higher Returns RNXT or ADMA?
ADMA Biologics, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of 27.14%. RenovoRx, Inc.'s return on equity of -127.86% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital RNXTRenovoRx, Inc.80.08% -$0.08 $8.3M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About RNXT or ADMA?
RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 479.43%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 37.63%. Given that RenovoRx, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe RenovoRx, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNXTRenovoRx, Inc.3 0 0 ADMAADMA Biologics, Inc.4 0 0 -
Is RNXT or ADMA More Risky?
RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock RNXT or ADMA?
RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNXT or ADMA?
RenovoRx, Inc. quarterly revenues are $266K, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. RenovoRx, Inc.'s net income of -$2.9M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 23.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 33.27x versus 9.97x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNXTRenovoRx, Inc.33.27x -- $266K -$2.9M ADMAADMA Biologics, Inc.9.97x 23.25x $134.2M $36.4M
-
Which has Higher Returns RNXT or DYAI?
Dyadic International, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of -169.67%. RenovoRx, Inc.'s return on equity of -127.86% beat Dyadic International, Inc.'s return on equity of -413.59%.
Company Gross Margin Earnings Per Share Invested Capital RNXTRenovoRx, Inc.80.08% -$0.08 $8.3M DYAIDyadic International, Inc.12.07% -$0.06 $7.7M -
What do Analysts Say About RNXT or DYAI?
RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 479.43%. On the other hand Dyadic International, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 600%. Given that Dyadic International, Inc. has higher upside potential than RenovoRx, Inc., analysts believe Dyadic International, Inc. is more attractive than RenovoRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNXTRenovoRx, Inc.3 0 0 DYAIDyadic International, Inc.1 0 0 -
Is RNXT or DYAI More Risky?
RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyadic International, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.569%.
-
Which is a Better Dividend Stock RNXT or DYAI?
RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyadic International, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. Dyadic International, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNXT or DYAI?
RenovoRx, Inc. quarterly revenues are $266K, which are smaller than Dyadic International, Inc. quarterly revenues of $1.2M. RenovoRx, Inc.'s net income of -$2.9M is lower than Dyadic International, Inc.'s net income of -$2M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while Dyadic International, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 33.27x versus 9.30x for Dyadic International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNXTRenovoRx, Inc.33.27x -- $266K -$2.9M DYAIDyadic International, Inc.9.30x -- $1.2M -$2M
-
Which has Higher Returns RNXT or GTBP?
GT Biopharma, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of --. RenovoRx, Inc.'s return on equity of -127.86% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital RNXTRenovoRx, Inc.80.08% -$0.08 $8.3M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About RNXT or GTBP?
RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 479.43%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1150%. Given that GT Biopharma, Inc. has higher upside potential than RenovoRx, Inc., analysts believe GT Biopharma, Inc. is more attractive than RenovoRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNXTRenovoRx, Inc.3 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is RNXT or GTBP More Risky?
RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock RNXT or GTBP?
RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNXT or GTBP?
RenovoRx, Inc. quarterly revenues are $266K, which are larger than GT Biopharma, Inc. quarterly revenues of --. RenovoRx, Inc.'s net income of -$2.9M is higher than GT Biopharma, Inc.'s net income of -$3.1M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 33.27x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNXTRenovoRx, Inc.33.27x -- $266K -$2.9M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns RNXT or PIII?
P3 Health Partners, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of -20.12%. RenovoRx, Inc.'s return on equity of -127.86% beat P3 Health Partners, Inc.'s return on equity of -223.63%.
Company Gross Margin Earnings Per Share Invested Capital RNXTRenovoRx, Inc.80.08% -$0.08 $8.3M PIIIP3 Health Partners, Inc.-13.2% -$9.67 $283.9M -
What do Analysts Say About RNXT or PIII?
RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 479.43%. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 102.97%. Given that RenovoRx, Inc. has higher upside potential than P3 Health Partners, Inc., analysts believe RenovoRx, Inc. is more attractive than P3 Health Partners, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNXTRenovoRx, Inc.3 0 0 PIIIP3 Health Partners, Inc.1 2 0 -
Is RNXT or PIII More Risky?
RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RNXT or PIII?
RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNXT or PIII?
RenovoRx, Inc. quarterly revenues are $266K, which are smaller than P3 Health Partners, Inc. quarterly revenues of $345.3M. RenovoRx, Inc.'s net income of -$2.9M is higher than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 33.27x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNXTRenovoRx, Inc.33.27x -- $266K -$2.9M PIIIP3 Health Partners, Inc.0.01x -- $345.3M -$69.5M
-
Which has Higher Returns RNXT or XNCR?
Xencor, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of -28.7%. RenovoRx, Inc.'s return on equity of -127.86% beat Xencor, Inc.'s return on equity of -20.07%.
Company Gross Margin Earnings Per Share Invested Capital RNXTRenovoRx, Inc.80.08% -$0.08 $8.3M XNCRXencor, Inc.87.62% -$0.08 $827.7M -
What do Analysts Say About RNXT or XNCR?
RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 479.43%. On the other hand Xencor, Inc. has an analysts' consensus of $28.00 which suggests that it could grow by 66.57%. Given that RenovoRx, Inc. has higher upside potential than Xencor, Inc., analysts believe RenovoRx, Inc. is more attractive than Xencor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNXTRenovoRx, Inc.3 0 0 XNCRXencor, Inc.9 1 0 -
Is RNXT or XNCR More Risky?
RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.97%.
-
Which is a Better Dividend Stock RNXT or XNCR?
RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNXT or XNCR?
RenovoRx, Inc. quarterly revenues are $266K, which are smaller than Xencor, Inc. quarterly revenues of $21M. RenovoRx, Inc.'s net income of -$2.9M is higher than Xencor, Inc.'s net income of -$6M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 33.27x versus 8.27x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNXTRenovoRx, Inc.33.27x -- $266K -$2.9M XNCRXencor, Inc.8.27x -- $21M -$6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
Sell
6
ODC alert for Dec 10
Oil-Dri Corp. of America [ODC] is up 3.07% over the past day.
Buy
84
PAAS alert for Dec 10
Pan American Silver Corp. [PAAS] is up 0.5% over the past day.
